In intestinal inflammation, TQ is an agonist of peroxisome proliferator-activated receptor-activated receptor-gamma (PPAR-γ), contributing to symptom relief, and indicating the possibility of using TQ as an adjuvant therapy in inflammatory bowel disease. Here, PPARG is linked to inflammatory response.